Welcome to our dedicated page for Quidel SEC filings (Ticker: QDEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
QuidelOrtho Corporation filings document an in vitro diagnostics company with Nasdaq-listed common stock under QDEL. Form 8-K disclosures cover quarterly and annual operating results, preliminary revenue estimates, financial guidance, Regulation FD communications and business commentary tied to point-of-care, labs, respiratory, cardiac and immunohematology diagnostics.
The company’s proxy and governance filings address annual meeting matters, board composition, executive compensation and shareholder voting information. Other current reports record leadership transitions, director changes, registered securities information and exhibit-based disclosures furnished with earnings releases and stockholder communications.
QuidelOrtho Corporation provides a detailed annual overview of its global diagnostics business, spanning Labs, Molecular Diagnostics, Point of Care and Transfusion Medicine across more than 140 countries. The company highlights U.S. manufacturing and service scale, including about 6,500 employees and roughly 1,200 service staff.
QuidelOrtho is winding down its U.S. donor screening portfolio, including the VIP platform and microplate assays, with completion expected by the first half of 2026, and has decided to discontinue development of the SAVANNA molecular platform. Respiratory products represented about 15% of total 2025 revenues, reflecting strong seasonality.
The company continues to invest in R&D, with expenses of $186.2 million, $218.7 million and $245.0 million for fiscal years 2025, 2024 and 2023, respectively. It recorded a $65 million charge payable to Grifols over three years tied to mutually agreed terms in principle for an early termination of their long‑running Joint Business arrangement. As of February 11, 2026, 68,081,767 common shares were outstanding, and the aggregate market value of common stock held by non‑affiliates was $1,940,523,408 as of the last business day of the most recent second fiscal quarter.
QuidelOrtho Corporation reported that its Chief Financial Officer and principal financial officer, Joseph M. Busky, has informed the company of his plans to retire, effective June 30, 2026. The company states that his decision is for personal reasons and not due to any disagreement regarding financial statements, operations, policies, or practices. This advance notice gives QuidelOrtho time to manage the transition in its senior financial leadership.
Strobeck Matthew reported open-market purchase transactions in a Form 4 filing for QDEL. The filing lists transactions totaling 10,000 shares at a weighted average price of $23.96 per share. Following the reported transactions, holdings were 27,775 shares.
QuidelOrtho Corporation received an amended ownership report showing that investment adviser Rubric Capital Management LP and David Rosen together beneficially own 3,777,157 shares of QuidelOrtho common stock, representing 5.56% of the outstanding shares.
The filing states Rubric Capital advises funds that hold these shares, including Rubric Capital Master Fund LP, which has the right to receive dividends or sale proceeds on more than 5% of the stock. The securities are reported as being acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of QuidelOrtho.
QuidelOrtho Corp’s Chief Financial Officer Joseph M. Busky reported an open‑market purchase of common stock. On February 13, 2026, a trust associated with him bought 3,370 shares at $23.6623 per share, bringing its indirect holdings to 10,290 shares and his direct holdings to 41,412 shares.
QuidelOrtho Corp President and CEO Brian J. Blaser reported an indirect open-market purchase of common stock through a trust associated with him. On February 13, 2026, the trust bought 10,540 shares at a weighted average price of $23.5921 per share, within a range of $23.4200 to $23.9400.
After this transaction, the trust held 40,073 shares of QuidelOrtho common stock indirectly for Blaser, while he also held 25,142 shares directly. The filing notes that detailed trade-by-trade pricing is available upon request from the reporting person.
Invesco Ltd. reports beneficial ownership of 3,470,656 shares of QuidelOrtho Corp common stock, representing 5.1% of the class as of 12/31/2025. Invesco has sole voting power over 3,450,932 shares and sole dispositive power over 3,470,656 shares, with no shared powers.
The shares are held of record by clients of Invesco’s investment advisers, including Invesco Advisers, Inc. and Invesco Capital Management LLC. Invesco certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of QuidelOrtho.
QuidelOrtho Corporation reported fourth-quarter and full-year 2025 results and issued 2026 guidance. Full-year 2025 revenue was $2.73 billion, slightly below 2024, as respiratory revenue fell 20% to $402.1 million with lower COVID-19 testing, while non-respiratory revenue reached $2.33 billion.
The company posted a 2025 GAAP net loss of $1.13 billion and a GAAP operating loss of $0.92 billion, driven largely by a $701 million non-cash goodwill impairment charge. Despite this, adjusted EBITDA was $597 million with a 22% adjusted EBITDA margin, a 240 basis point improvement.
Free cash flow was $(77) million in 2025, reflecting one-time ERP system investments, but management expects free cash flow to improve by over $200 million in 2026, guiding to $120–$160 million. 2026 guidance calls for $2.7–$2.9 billion in revenue, adjusted EBITDA of $630–$670 million, and adjusted EPS of $2.00–$2.42. The company also announced that Chief Financial Officer Joseph M. Busky plans to retire effective June 30, 2026.
QuidelOrtho Corp Chief Legal Officer reports equity award vesting and tax withholding. On February 8, 2026, Michelle A. Hodges had 3,198 restricted stock units convert into an equal number of common shares at a stated price of $0, increasing her directly held stake.
In connection with this vesting, 1,148 common shares were disposed of at $29.10 per share to cover tax withholding obligations, rather than being an open-market sale. After these transactions, Hodges directly owned 41,605 shares of QuidelOrtho common stock.
QuidelOrtho Corp Chief Financial Officer Joseph M. Busky reported equity compensation activity involving restricted stock units and common shares. On February 8, 2026, 5,968 restricted stock units were converted into 5,968 shares of common stock at a stated price of $0.
In connection with this release, 1,806 common shares at $29.1 per share were withheld by the issuer to satisfy tax withholding obligations, leaving Busky with 41,412 common shares held directly. He also reports 6,920 common shares held indirectly by a trust.
The filing notes that 5,968 shares vested on each of February 8, 2025 and February 8, 2026, and 5,969 additional shares are scheduled to vest on February 8, 2027, reflecting an ongoing multi‑year restricted stock unit vesting schedule.